Coronary artery disease (CAD) is due to subintimal deposition of atheromatous plaques in large and mediumsized coronary arteries. Different risk factors have been identified such as hypertension, hypercholesterolemia, diabetes and smoking. Both hypertension and diabetes mellitus affect the same major target organs. The common hypertensive/ diabetic target is the vascular tree, hence renal function is particularly exposed in these patients and often reduced by vascular injury. Consequently, renal protection is a major concern for patients with CAD and/or diabetes who are facing vascular or abdominal surgery, potential nephrotoxic treatment or contrast agents-induced nephropathy. Ischemia reperfusion injury (IRI) is also a common and important clinical cause of renal disease such as renal transplantation and following shock from any cause. Acute renal failure and chronic renal insufficiency are significant complications associated with prolonged warm ischemia (WI). The WI duration remains the most important factor governing the return of postoperative renal function in surgical procedure in which renal blood flow is interrupted. Beside traditional therapy, metabolic therapy is another approach for the treatment of myocardial ischemia at the cellular level itself, with agents that have the capacity to exert their action on the cell without affecting the hemodynamic condition. Such therapies could also be of major interest in the prevention of renal damage and limitation of long term effect of renal IRI, particularly for patients with reduced functional nephron mass. The absence of hemodynamic effect is useful in situations such as shock.
Keywords: Renal failure, renal ischemia reperfusion injury, metabolic therapy, coronary artery disease, diabetes, renal protection, cold preservation, trimetazidine
The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design In Silico Bioactivity Prediction of Methoxime-3,4-dephostatin Derivatives on Human PTP1B: Search for Novel Antidiabetic Leads
Letters in Drug Design & Discovery SIRT1 – An Anti-Inflammatory Pathway at the Crossroads Between Metabolic Disease and Atherosclerosis
Current Vascular Pharmacology Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry Is Relief from Diabetes Just a Breath Away … ?
Current Drug Delivery Hypertensive Treatment and the Metabolic Syndrome
Current Hypertension Reviews Role of Immune Cells in Diabetic Kidney Disease
Current Gene Therapy EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Current Status and Perspectives in Ceramide-Targeting Molecular Medicine
Current Pharmaceutical Design Cystic Fibrosis Related Diabetes Mellitus - Diagnostic and Management Challenges
Current Diabetes Reviews The Role of Diabetes Mellitus in Sexual and Reproductive Health: An Overview of Pathogenesis, Evaluation, and Management
Current Diabetes Reviews Differential Expression of Genes in Obesity and Type 2 Diabetes Mellitus
Current Nutrition & Food Science Pleiotropic Effects of HDL: Towards New Therapeutic Areas for HDL-Targeted Interventions
Current Molecular Medicine Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes
Current Drug Targets Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Mediterranean Diet Rich in Olive Oil and Obesity, Metabolic Syndrome and Diabetes Mellitus
Current Pharmaceutical Design Obesity: Pathophysiology and Clinical Management
Current Medicinal Chemistry Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Current Vascular Pharmacology